A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression
- PMID: 38751415
- PMCID: PMC11094466
- DOI: 10.3389/fpsyt.2024.1289630
A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression
Abstract
Introduction: Despite the development of many successful pharmaceutical interventions, a significant subset of patients experience treatment-resistant depression (TRD). Ketamine and its derivatives constitute a novel therapeutic approach to treat TRD; however, standard tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) are still being used to measure symptoms and track changes.
Methods: The aim of this study was to review item-level differences between rate of data change (MADRS score) and rater-weighted perception of the most useful items for assessing change in symptoms while remotely conducting the 10-item version of the MADRS in TRD in a clinical trial of rapid-acting antidepressants. Two studies of rapid-acting antidepressants in the treatment of TRD were used to identify item-scoring trends when MADRS is administered remotely and repeatedly (733 subjects across 10 visits). Scoring trends were evaluated in tandem to a rater survey completed by 75 raters. This was completed to gain insight on MADRS items' perceived level of helpfulness when assessing change of symptoms in rapid-acting antidepressant trials.
Results: MADRS items 'Reduced sleep', 'Apparent sadness', and 'Pessimistic thoughts' were found to have the greatest average data change by visit, while raters ranked 'Reported sadness', 'Lassitude' and 'Apparent sadness' as the most helpful items when assessing symptom change.
Discussion: The diversion between rate of data-change ranking and rater perception of helpfulness could be related to difficulty in assessing specific items, to the novel treatment itself, and/or to the sensitivity to symptom change to which raters are accustomed in traditional antidepressant treatments.
Keywords: MADRS = Montgomery-Asberg depression rating scale; depression; rapid acting antidepressants; rater perception; structured interview guide for the MADRS (SIGMA).
Copyright © 2024 Capodilupo, Blattner, Must, Navarro and Opler.
Conflict of interest statement
GC, RB and SN are employed by WCG Clinical Endpoint Solutions. AM is a contractor of WCG Clinical Endpoint Solutions and a part-time employee of Whanganui District Health Board, Whanganui, NZ. MO is employed by WCG Clinical Endpoint Solutions; has received royalties from Pearson Inc. from sales of the PANSS Manual; and has received past grant funding from NIH, Brain & Behavior Foundation, the Stanley Medical Research Institute, and the Qatar National Research Fund. The reviewer WL declared a past co-authorship with the author MO to the handling editor.
Figures

Similar articles
-
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.CNS Drugs. 2022 Jun;36(6):649-658. doi: 10.1007/s40263-022-00916-2. Epub 2022 Apr 20. CNS Drugs. 2022. PMID: 35441931 Free PMC article. Clinical Trial.
-
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.Int J Methods Psychiatr Res. 2022 Dec;31(4):e1927. doi: 10.1002/mpr.1927. Epub 2022 Jun 24. Int J Methods Psychiatr Res. 2022. PMID: 35749277 Free PMC article. Clinical Trial.
-
Inter-rater reliability among psychiatrists when assessing depression according to the Montgomery-Åsberg Depression Rating Scale.Nord J Psychiatry. 2021 Nov;75(8):607-613. doi: 10.1080/08039488.2021.1918240. Epub 2021 Jun 22. Nord J Psychiatry. 2021. PMID: 34156321
-
Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.Cureus. 2024 Feb 10;16(2):e53987. doi: 10.7759/cureus.53987. eCollection 2024 Feb. Cureus. 2024. PMID: 38476783 Free PMC article. Review.
-
Pharmacological interventions for treatment-resistant depression in adults.Cochrane Database Syst Rev. 2019 Dec 17;12(12):CD010557. doi: 10.1002/14651858.CD010557.pub2. Cochrane Database Syst Rev. 2019. PMID: 31846068 Free PMC article.
Cited by
-
Impact of genetic counseling and testing in individuals at high risk of familial Alzheimer's disease from Latin America: a non-randomized controlled trial.Alzheimers Dement (Amst). 2025 Apr 6;17(2):e70102. doi: 10.1002/dad2.70102. eCollection 2025 Apr-Jun. Alzheimers Dement (Amst). 2025. PMID: 40201594 Free PMC article.
References
-
- Food & Drug Administration . FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. (2019).
-
- World Health Organization . Depression and other common mental disorders: global health estimates (No. WHO/MSD/MER/2017.2) (2017). Available online at: https://apps.who.int/iris/handle/10665/254610 (Accessed September 5, 2023).
LinkOut - more resources
Full Text Sources